EGFR and non-small cell lung carcinoma: First-generation (gefitinib, erlotinib and icotinib) and second-generation (afatinib and dacomitinib) EGFR-TKIs have demonstrated substantial clinical benefit in advanced NSCLC patients with Ex19del and L858R mutations [7, 8].